Corcept Therapeutics Shares Surge on FDA Nod for Ovarian Cancer Drug
Corcept Therapeutics shares surged after its lead drug received approval from the FDA for the treatment of ovarian cancer, marking a significant milestone for the company.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)Sources
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - Reuters
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer Reuters
Read full article →Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
Read full article →Coverage Timeline
Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now

Four Arrested for Selling P102 Million in Counterfeit Anti-Cancer Medicine in Makati
just now

Philippines receives diesel shipment from Malaysia
just now

Frozen Fish Initiative Reaches 50 Cities as Morocco Plans Permanent Network
12m ago